Page last updated: 2024-12-08
tripalmitoyl cysteine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
tripalmitoyl cysteine: synthetic analog of N-terminal lipid part of bacterial lipoprotein [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 135864 |
MeSH ID | M0116693 |
Synonyms (15)
Synonym |
---|
l-cysteine, s-(2,3-bis((1-oxohexadecyl)oxy)propyl)-n-(1-oxohexadecyl)-, methyl ester |
(2,3-bis(palmitoyloxy)propyl)-n-palmitoylcysteine methyl ester |
tripalmitoyl-s-glyceryl cysteine |
tripalmitoyl cysteine |
87079-94-5 |
[3-[(2r)-2-(hexadecanoylamino)-3-methoxy-3-oxopropyl]sulfanyl-2-hexadecanoyloxypropyl] hexadecanoate |
3-(((r)-3-methoxy-3-oxo-2-palmitamidopropyl)thio)propane-1,2-diyl dipalmitate |
DTXSID601007318 |
n-(3-{[2,3-bis(hexadecanoyloxy)propyl]sulfanyl}-1-methoxy-1-oxopropan-2-yl)hexadecanimidic acid |
AKOS040754268 |
pam3cys (synthetic) |
hexadecanoic acid, 1-[[[(2r)-3-methoxy-3-oxo-2-[(1-oxohexadecyl)amino]propyl]thio]methyl]-1,2-ethanediyl ester |
tripalmitoyl-s-glyceryl-cysteine (synthetic) |
3-{[(2r)-3-methoxy-3-oxo-2-(palmitoylamino)propyl]sulfanyl}-1,2-propanediyldihexadecanoate |
6F2GL65JK2 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (13)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (7.69) | 18.7374 |
1990's | 4 (30.77) | 18.2507 |
2000's | 7 (53.85) | 29.6817 |
2010's | 1 (7.69) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.15
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.15) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |